Skip to main content

Table 4 The Incidence of Carriage and Healthcare-Associated Infection of MDRO per 1000 Patient-Days were Determined in the Pre-intervention Period and During the Intervention Period

From: Implementation of human factors engineering approach to improve environmental cleaning and disinfection in a medical center

  The incidence of MDRO per 1000 patient-days 
 nPre-intervention periodaIntervention periodbP
Carriage
 Overall284.1 (564/136794)3.6 (507/140860).03
  VRE 1.8 (253/136794)1.3 (184/140860)< .001
  MRSA 1.3 (178/136794)1.2 (171/140860).55
  CRABC 1.0 (133/136794)1.1 (152/140860).41
 General wards193.7 (421/114141)3.4 (403/117894).29
  VRE 1.8 (209/114141)1.3 (152/117894)< .001
  MRSA 1.2 (136/114141)1.2 (147/117894).75
  CRABC 0.7 (76/114141)0.9 (104/117894).07
 ICUs96.3 (143/22653)4.5 (104/22966).01
  VRE 1.9 (44/22653)1.4 (32/22966).19
  MRSA 1.9 (42/22653)1.0 (24/22966).03
  CRABC 2.5 (57/22653)2.1 (48/22966).39
Healthcare-associated infection
 Overall280.3 (47/136794)0.4 (62/140860).23
 General wards190.3 (30/114141)0.4 (44/117894).17
 ICUs90.8 (17/22653)0.8 (18/22966).97
  1. NOTE. MDRO multiple-drug resistant organism, including vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and carbapenem-resistant Acinetobacter baumannii complex (CRABC)
  2. aJuly 2016 to January 2017
  3. bMarch 2017 to September 2017
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us